Thank you everyone for making the 9th International Lung Cancer Network Conference, in Athens a success! This is a sincere gratitude message to all of you, the faculty members, the attendees, the sponsors, and of course the organizers.

New #JITC article: Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck bit.ly/45evnMs

Research from Yale Cancer Center on a three-drug regimen in anti-PD-1-resistant #melanoma shows that higher doses were inferior to lower doses, and dose optimization is necessary for this patient population. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp Yale Pathology molecular-cancer.biomedcentral.com/articles/10.11…

In Annals of Oncology, Niki Gavrielatou Amanda Psyrri and coll. report #OpenAccess on a study evaluating biomarkers of patient outcome on PD-1-based immunotherapy in platinum-refractory head and neck squamous cell cancer annalsofoncology.org/article/S0923-… George Coukos @RimmPathology

#mdpijpm 💝Enjoy today's #Editor_Choice Paper "CD24: A Novel Target for Cancer Immunotherapy" 👥Emmanouil Panagiotou et al. University of Athens 👉More info: mdpi.com/1747790 MDPI MDPI Medicine & Pharmacology

"#Together we stand, divided we fall..." Thank you @myesmo, Raffaele Califano and all renowned speakers for this excellent preceptorship! Until next time! #lungcancer #collaboration #european #power #oncology #research #advances #TheChristieSoO #TheChristieNHS #oneteam #ESMO

New #JITC article: High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC) bit.ly/3RlgQdo Myrto K. Moutafi Thazin Nwe Aung, PhD @rolando_milian Ioannis Vathiotis Athanasios Angelakis

A significant proportion of #lungcancer occurs in #neversmokers, & #lungcancer is significantly more common among those with a positive family history, especially for #early-onset #disease. This highlights the role of #inherited #genetic #factors as one of the notable causes of

A new study from Dr. Thazin Nwe Aung Thazin Nwe Aung, PhD finds spatially-defined compartment signatures utilize tumor and tumor microenvironment-specific information, leading to more accurate prediction of treatment outcome in #melanoma. aacrjournals.org/clincancerres/… Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp

Amazing Presidential Symposium ESMO - Eur. Oncology. Eyes to the future, biomarkers in the spotlight: precision oncology, AI, organ preservation approaches and emerging therapeutic targets. The future is bright - collaboration and access will be key!

Stage III ALK+ NSCLC: consolidation ALK TKI v Durva v Obs JTO & JTO CRR: -67pts, ALKi=15 Durva=30 obs=22 -mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001) Small n, but useful OncoAlert Amin Nassar, MD #LCSM jto.org/article/S1556-…

Another proof of concept that adjuvant component of perioperative IO is NOT for all: NOT adding benefit to patients who achieve PCR and NOT enough for patients without MPR/PCR…Room for deescalation for PCR patients and for escalation strategies in non-PCR/ MPR?? Congrats

Retrospective report in European Journal of Cancer on #EGFR mutant NSCLC transformed to #SCLC. Post transformation, 93% were DLL3 positive. Are BiTEs like tarlatamab viable options here? No clear current standard (chemo, chemo + TKI, chemo + IO). ejcancer.com/article/S0959-…

New test developed for #breastcancer by @RimmPathology at Yale School of Medicine may allow for more personalized #lungcancer therapy. “The way we did this measurement was by using cell line standards, which is a bit novel,” Dr. Rimm tells HemOnc Today. Yale Cancer Center bit.ly/3Z3FqU8

Phase I/II SOHO-01: BAY 2927088 in HER2m NSCLC. In HER2i-naive (cohort D): ORR 70.5%, DoR 8.7 mo. EGFRi-like AEs (rash, diarrhea). Busy Ph3 landscape: TKIS (SOHO-02, WU-KONG28 FURMO-004) or TKIs + ChT (REZILIENT3) vs SoC in 1L HER2m NSCLC #ESMOAmbassadors #ELCC25 ESMO - Eur. Oncology

I am truly thrilled and humbled to be nominated as a candidate for the IASLC Board of Directors (Basic Science). IASLC has been my professional home for nearly a decade—a place that has shaped my journey as a #scientist, #mentor, and #collaborator. I have met some of the most

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Great publication paving the way into the future! Proud to be co-author! Congrats to Dr. Sen the group! Just published in JTO.

Excited to share our review on "Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity" in JTO & JTO CRR. We examine how #LUAD transforms into #SCLC or #LUSC under treatment pressure as a key factor in #resistance, and unpack the #genetic, #epigenetic,